Does keytruda's effectiveness diminish with prolonged use?

Does Keytruda lose strength over time

Keytruda works by blocking the PD-1 protein on immune cells, allowing them to keep attacking cancer cells. Over months or years of use, some tumors develop ways to bypass this checkpoint, so the drug's effect can weaken. Doctors track this through imaging and blood markers, and when progression occurs they may switch to another therapy or add a second drug.

Can resistance develop even after a strong initial response

Yes. Clinical studies show that roughly one-third of patients who respond well at first later experience disease progression on Keytruda alone. Mechanisms include loss of beta-2-microglobulin, changes in interferon signaling, or new mutations that hide tumor antigens. Re-testing the tumor at progression sometimes reveals these escape routes.

What happens if Keytruda stops working

If scans show growth or new lesions, oncologists usually stop Keytruda or combine it with chemotherapy, another checkpoint inhibitor, or a targeted agent matched to new tumor mutations. In some cases, a short treatment break followed by re-challenge can regain control, but durable second responses are less common than the first.

How long do most patients stay on Keytruda

Many protocols allow treatment up to two years if the cancer remains controlled. Some patients with complete responses stop earlier under a “stop-and-watch” approach. When the cancer returns after stopping, restarting Keytruda can work for a subset of patients, yet overall response rates drop compared with continuous use.

Do biosimilars or next-generation PD-1 drugs change this picture

Several PD-1 biosimilars are in late-stage trials, and next-generation agents aim to block additional checkpoints or deliver immune-stimulating payloads directly to tumors. These candidates could delay or overcome resistance, but none have yet shown clear superiority over Keytruda in large head-to-head studies.

When does Keytruda's main patent expire

The primary U.S. composition-of-matter patent for pembrolizumab expires in 2028, with some method-of-use patents extending to 2032. After these dates, biosimilar competition is expected to increase, which may affect pricing and access but will not directly alter the biological problem of resistance.

[1] https://www.drugpatentwatch.com/drug/pembrolizumab